Collateral damage. The rise of resistant C. difficile.
Taubes
Gary
G
D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002170:Canada / Q000453:epidemiology; D016360:Clostridioides difficile / Q000187:drug effects* / Q000472:pathogenicity; D003015:Clostridium Infections / Q000453:epidemiology / Q000382:microbiology*; D003428:Cross Infection / Q000453:epidemiology / Q000382:microbiology*; D004196:Disease Outbreaks; D024881:Drug Resistance, Bacterial; D004761:Enterocolitis, Pseudomembranous / Q000453:epidemiology / Q000382:microbiology*; D005060:Europe / Q000453:epidemiology; D006801:Humans; D014481:United States / Q000453:epidemiology
D000900:Anti-Bacterial Agents